Polymerizable photoinitiators and radiation curable compositions
    3.
    发明授权
    Polymerizable photoinitiators and radiation curable compositions 有权
    可聚合光引发剂和可辐射固化组合物

    公开(公告)号:EP2199273B1

    公开(公告)日:2018-02-21

    申请号:EP08172104.5

    申请日:2008-12-18

    申请人: AGFA NV

    摘要: A polymerizable photoinitiator represented by Formula (I): and wherein R1, R2 and R3 are independently selected from the group consisting of a hydrogen, an optionally substituted alkyl group and an optionally substituted aryl group or R1 and R3 represent the necessary atoms to form a five to eight membered ring; p, w, y and z are all integers with y representing a value 1 to 6; p representing the sum of w and z; p representing a value of 1 to 6; w = 1 to (p-z) and z = 0 to (p-w); L represents an optionally substituted (p+y)-valent linking group comprising 1 to 14 carbon atoms; A represents a radically polymerizable group selected from the group consisting of an acrylate group, a methacrylate group, a styrene group, an acryl amide group, a methacryl amide group, a maleate group, a fumarate group, an itaconate group, a vinyl ether group, an allyl ether group, an allyl ester group and a vinyl ester group; and X represents a photoinitiating moiety including at least one group capable of initiating a free radical polymerization reaction upon exposure to actinic radiation. Radiation curable compositions including the polymerizable photoinitiator and methods of preparing the polymerizable photoinitiator are also disclosed.

    LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT
    9.
    发明公开
    LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT 审中-公开
    脂类化合物,其用在化妆品中AS食物补充剂或作为药物

    公开(公告)号:EP2217224A4

    公开(公告)日:2015-10-07

    申请号:EP08846228

    申请日:2008-11-06

    摘要: The present disclosure relates to lipid compounds of formula (I): wherein: R1 is chosen from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and are chosen from hydrogen and a C1-C6 alkyl; X is chosen from O, S, SO, SO2, Si, and Se; n=1 or 3; and P1 is chosen from hydrogen; a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P2, P3, and P4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P5 is chosen from hydrogen and a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and methods of use thereof, for example in the treatment of diseases related to cardiovascular, metabolic, and inflammatory conditions.

    摘要翻译: 本发明涉及式I的脂质化合物(I):worin:R 1选自C10-C21烷基选择,具有1-6个双键,且具有1-6个三键的C10-C21炔一个C10-C21链烯基; R2和R3是相同或不同,选自氢和C1-C6烷基被选择; X选自O,S,SO,SO 2,硅,硒和选择; n = 1或3; 和P1选自氢; 一个C10-C21烷基,具有1-6个双键的C10-C21链烯基,具有1-6个三键的C10-C21炔基,任选substituiertem; 式的基团(II)或式(III),worin P2,P3,和P4被选自氢,substituiertem的烷基,以烯基,炔选择并于,任选; 和一组式(IV)或式(V)的,worin P5选自氢和C1-C6烷基选择; 或药学上可接受的盐,复合物,或溶剂合物。 所以圆盘游离缺失是药物组合物和脂质组合物,包含测试的化合物,以及它们的使用方法,对于相关的心血管,代谢和炎性病症的疾病的治疗实施例。